UXI:ARCA-ProShares Ultra Industrials

ETF | Drug Manufacturers | NYSE Arca

Last Closing

USD 77.3

Change

-0.97 (-1.24)%

Market Cap

USD 0.02B

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. IndustrialsSM Index. The fund invests in securities and derivatives that ProShare Advisors believes, in combination, should have similar daily return characteristics as two times (2x) the daily return of the index. The index measures the performance of the industrial sector of the U.S. equity market. The fund is non-diversified.

Inception Date: 30/01/2007

Primary Benchmark: DJ US Industrials TR USD

Primary Index: S&P 500 TR USD

Gross Expense Ratio: 1.63%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2019-10-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Mer Price(Change) Market Cap
SCYB Schwab Strategic Trust 0.00 %

+0.15 (+0.29%)

N/A

ETFs Containing UXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 47.81% 92% A 93% A
Dividend Return 0.76% 41% F 12% F
Total Return 48.57% 95% A 93% A
Trailing 12 Months  
Capital Gain 12.93% 76% C+ 74% C
Dividend Return 0.78% 26% F 10% F
Total Return 13.71% 74% C 71% C-
Trailing 5 Years  
Capital Gain 138.51% 88% B+ 93% A
Dividend Return 3.57% 50% F 12% F
Total Return 142.08% 85% B 92% A
Average Annual (5 Year Horizon)  
Capital Gain 19.89% 92% A 92% A
Dividend Return 20.29% 92% A 91% A-
Total Return 0.40% 44% F 10% F
Risk Return Profile  
Volatility (Standard Deviation) 28.09% 16% F 22% F
Risk Adjusted Return 72.24% 79% B- 76% C+
Market Capitalization 0.02B 47% F 11% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.